Last reviewed 2026-04-19 · How we verify

CART-PSMA cells

Nova Therapeutics LLC · Phase 1 active Small molecule

At a glance

Generic name	CART-PSMA cells
Also known as	No other names
Sponsor	Nova Therapeutics LLC
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

CART-PSMA-TGFβRDN Cells for Castrate-Resistant Prostate Cancer (PHASE1)
Intervention of Bladder Cancer by CAR-T (PHASE1, PHASE2)
CART-PSMA Cells for Advanced Prostate Cancer (PHASE1)
Clinical Study of Safety and Efficacy of Enhanced PSMA CAR- T in Refractory CRPC (EARLY_PHASE1)
LIGHT-PSMA-CART in Treating Patients With Castrate-Resistant Prostate Cancer (PHASE1)
A Study of CART-PSMA-TGFβRDN in Patients With Metastatic Castration Resistant Prostate Cancer (PHASE1)
PD1 Integrated Anti-PSMA CART in Treating Patients With Castrate-Resistant Prostate Cancer (PHASE1)
4SCAR-T Therapy Targeting GD2, PSMA and CD276 for Treating Neuroblastoma (PHASE1, PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results